Faes Farma : FY 2022 results meet guidance but Q4 misses ours and consensus numbers
>Sales show some sequential improvement, but margins hit by inflation and commercial expenses - Total Q4 2022 revenues reached € 110m (+2% y-o-y vs -6% sales growth registered in Q3), beating our estimates yet aligned with the consensus. By division, sales of traditional products in Spain posted some sequential improvement yet remained in the red (-7% y-o-y in Q4 2022 vs -9% in Q3), reflecting stagnant sales of Hidroferol (vitamin D) and declining Bilastine revenues i...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.